Drugs / Doxorubicin liposome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04172259 | Jan 2019 → Sep 2023 overdue | breast cancer | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05164770 Comparator | Mar 2021 → Dec 2023 | high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, mantle cell lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| — | NCT05809180 Background | Jan 2023 → Jul 2025 | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxorubicin Liposome | “doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2;” NCT05809180 ↗ |
| Route | Intravenous | “doxorubicin liposome 15 mg/m2 ivgtt d2;” NCT05809180 ↗ |